Renal denervation in patients with chronic kidney disease: current evidence and future perspectives
Open accessThe DOI matches its Crossref record; 64 of the 65 references it cites were found in a registry or an index.
Abstract
Supported by several high-quality randomized controlled trials and registry analyses, catheter-based renal denervation is becoming an important adjunctive treatment modality for the safe and efficacious treatment of hypertension besides lifestyle modifications and antihypertensive medication. Renal denervation is of particular interest to nephrologists as the intervention may provide additional benefits to hypertensive people with chronic kidney disease (CKD), a condition typically characterized by sympathetic hyperactivity. A growing body of clinical evidence supports the safety and efficacy of renal denervation in this difficult-to-control population. In addition, preclinical and clinical research works indicate potential nephroprotective effects in CKD patients. The current review examines recent research on renal denervation with a focus on renal disease and assesses the latest findings and their implications from a nephrologist's perspective.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![FIGURE 1: Effect of bilateral nephrectomy on SNS activity in renal transplant patients. From Hausberg et al [12]. MSNA, muscle sympathetic activity; CVR, calf vascular resistance; n.s., not significant.](https://figures.cochat.ai/paper-figures/ebf935d0df6749fe90c2ea67d30ad069/renal-denervation-in-patients-with-chronic-kidney-disease-current-evidence-and-figure-1.jpg)

![FIGURE 3: Changes from baseline with renal denervation or sham up to 36 months in the randomized, sham-controlled SPYRAL-ON MED study. Medication changes were allowed after end of primary follow-up at 6 months and patients were unblinded to randomization status at 12 months. Adapted from Mahfoud et al [27].](https://figures.cochat.ai/paper-figures/afc12b7691ca453993712996b741cff9/renal-denervation-in-patients-with-chronic-kidney-disease-current-evidence-and-figure-3.jpg)
![FIGURE 4: Muscle sympathetic nerve activity (MSNA) expressed as burst frequency (bs/min; blue bars; left-hand scale) and burst incidence (bs/100 heartbeats; green bars; right-hand scale) in patients and healthy individuals grouped according to progressively more severe degrees of renal dysfunction. Adapted from Grassi et al [43].](https://figures.cochat.ai/paper-figures/718d520b7d7942d49274119fde9a8c14/renal-denervation-in-patients-with-chronic-kidney-disease-current-evidence-and-figure-4.jpg)
![FIGURE 5: Mean basal total urinary NOx (nitrate + nitrite) excretion (V) in normotensive (control) and hypertensive sheep with CKD 2 and 30 months after renal denervation or sham procedures, respectively. Lines indicate standard error. *P < .05 comparing sham groups at follow-up. ##P < .05, ####P < .0001 comparing sham and treated groups at follow-up. From Singh et al [58].](https://figures.cochat.ai/paper-figures/0425e9ce69d2475d9ef8ec20b2f7a4bd/renal-denervation-in-patients-with-chronic-kidney-disease-current-evidence-and-figure-5.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“As large clinical trials of RDN have excluded patients with GFR <45 ml/min/1.73 m2 (ref. 119), the efficacy of this approach in patients with kidney failure is difficult to discern.”
From Renal nerves in physiology, pathophysiology and interoception (2025) · cites this paper as [119]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2018 ESC/ESH Guidelines for the management of arterial hypertension
Williams, B., Mancia, G., Spiering, W., Agabiti Rosei, E., Azizi, M., Burnier, M., Clement, D. L., Coca, A., de Simone, G., Dominiczak, A., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy339 · Cited by 10,286
Self-citationBikbov, B., Purcell, C. A., Levey, A. S., Smith, M., Abdoli, A., Abebe, M., Adebayo, O. M., Afarideh, M., Agarwal, S. K., Agudelo-Botero, M., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30045-3 · Cited by 6,648
A Controlled Trial of Renal Denervation for Resistant Hypertension
Bhatt, D. L., Kandzari, D. E., O'Neill, W. W., D'Agostino, R., Flack, J. M., Katzen, B. T., Leon, M. B., Liu, M., Mauri, L., Negoita, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402670 · Cited by 2,186
Krum, H., Schlaich, M., Whitbourn, R., Sobotka, P. A., Sadowski, J., Bartus, K., Kapelak, B., Walton, A., Sievert, H., Thambar, S., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60566-3 · Cited by 2,108
Sympathetic Overactivity in Patients with Chronic Renal Failure
Converse, R. L., Jacobsen, T. N., Toto, R. D., Jost, C. M. T., Cosentino, F., Fouad-Tarazi, F., & Victor, R. G. (1992) · New England Journal of Medicine · doi:10.1056/nejm199212313272704 · Cited by 1,132 · cited 2×
“This increase in GFR was accompanied by a sustained reduction in MAP; conversely there was a continual increase in MAP with time in sham-treated sheep.”
BackgroundKandzari, D. E., Böhm, M., Mahfoud, F., Townsend, R. R., Weber, M. A., Pocock, S., Tsioufis, K., Tousoulis, D., Choi, J. W., East, C., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30951-6 · Cited by 793
Self-citationTownsend, R. R., Mahfoud, F., Kandzari, D. E., Kario, K., Pocock, S., Weber, M. A., Ewen, S., Tsioufis, K., Tousoulis, D., Sharp, A. S. P., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32281-x · Cited by 752
Self-citationAzizi, M., Schmieder, R. E., Mahfoud, F., Weber, M. A., Daemen, J., Davies, J., Basile, J., Kirtane, A. J., Wang, Y., Lobo, M. D., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31082-1 · Cited by 740
Self-citationBöhm, M., Kario, K., Kandzari, D. E., Mahfoud, F., Weber, M. A., Schmieder, R. E., Tsioufis, K., Pocock, S., Konstantinidis, D., Choi, J. W., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30554-7 · Cited by 606
Self-citationPredictors of blood pressure response in the SYMPLICITY HTN-3 trial
Kandzari, D. E., Bhatt, D. L., Brar, S., Devireddy, C. M., Esler, M., Fahy, M., Flack, J. M., Katzen, B. T., Lea, J., Lee, D. P., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehu441 · Cited by 546 · cited 1×
“The latter two confounders would explain the substantial BP reductions in the sham group [17, 18].”
Background
Cited by
Mancia, G., Kreutz, R., Brunström, M., Burnier, M., Grassi, G., Januszewicz, A., Muiesan, M. L., Tsioufis, K., Agabiti-Rosei, E., Algharably, E. A. E., et al. (2023) · Journal of Hypertension · doi:10.1097/hjh.0000000000003480 · Cited by 3,473
Self-citationHypertension in chronic kidney disease—treatment standard 2023
Georgianos, P. I., & Agarwal, R. (2023) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfad118 · Cited by 116
Diagnosis and management of resistant hypertension
Schiffrin, E. L., & Fisher, N. D. L. (2024) · BMJ · doi:10.1136/bmj-2023-079108 · Cited by 81
Sympathetic Nervous System and Atherosclerosis
Wang, Y., Anesi, J., Maier, M. C., Myers, M. A., Oqueli, E., Sobey, C. G., Drummond, G. R., & Denton, K. M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241713132 · Cited by 55
Renal nerves in physiology, pathophysiology and interoception
Evans, L. C., Dayton, A., & Osborn, J. W. (2025) · Nature Reviews Nephrology · doi:10.1038/s41581-024-00893-3 · Cited by 46
“119), the efficacy of this approach in patients with kidney failure is difficult to discern.”
Renal denervation for hypertension
Fisher, N. D. L., & Kirtane, A. J. (2025) · Nature Reviews Cardiology · doi:10.1038/s41569-024-01104-z · Cited by 45
“At this time, limited data are available to support the use of RDN in certain patient populations, including those with an estimated glomerular filtration rate 40 ml/min/1.73 m 2 , although smaller studies have shown safety and efficacy in patients with impaired renal function 81,82 .”
InfluentialRenal Denervation in Patients With Moderate to Severe Chronic Kidney Disease
Schlaich, M. P., Mahfoud, F., Böhm, M., Narkiewicz, K., Ruilope, L. M., Williams, B., Mancia, G., Sharif, F., Ribichini, F. L., Lung, T., et al. (2025) · Hypertension · doi:10.1161/hypertensionaha.125.25470 · Cited by 20
“3 7 Furthermore, hypertension is reported to be resistant to treatment in 40% to 50% of patients with CKD. 6,8,9 18–21 Studies applying state-of-the-art assessment of muscle sympathetic nerve activity and norepinephrine spillover documented substantial and sustained reduction of sympathetic…”
Self-citationFeriozzi, S., Battaglia, Y., Cirami, C. L., Gangemi, C., Manna, G. L., Gesualdo, L., Muiesan, M. L., Pani, A., Pieruzzi, F., Ribichini, F. L., et al. (2025) · Journal of Nephrology · doi:10.1007/s40620-025-02406-2 · Cited by 12
Renal denervation in dialysis patients: long-term outcomes in a real-world setting
Gangemi, C., Gambaro, A., Ortalda, V., Tavella, D., Caletti, C., Fezzi, S., Bianco, B., Tomi, E. D., Gambaro, G., Ribichini, F. L., et al. (2025) · Clinical Kidney Journal · doi:10.1093/ckj/sfaf149 · Cited by 10
Blood pressure reduction after renal denervation in patients with or without chronic kidney disease
Günes-Altan, M., Schmid, A., Ott, C., Bosch, A., Pietschner, R., Schiffer, M., Uder, M., Schmieder, R. E., & Kannenkeril, D. (2023) · Clinical Kidney Journal · doi:10.1093/ckj/sfad237 · Cited by 10
“Interruption of the pathogenetic pathway of the progressive decline of renal function may attenuate the progression of CKD [12 ,13 ].”
BackgroundSelf-citationIliakis, P., Dimitriadis, K. S., Tatakis, F., Vakka, A., Sakalidis, A., Pyrpyris, N., Fragoulis, C., Konstantinidis, D., Aznaouridis, K. A., & Tsioufis, K. P. (2025) · Biomedicines · doi:10.3390/biomedicines13081951 · Cited by 11
“Chronic kidney disease is strongly associated with resistant hypertension [4].”
2025 Update on resistant hypertension in CKD: where do we stand and where do we go?
Schmieder, R. E. (2025) · Clinical Kidney Journal · doi:10.1093/ckj/sfaf285 · Cited by 9
“Three pilot studies reported a stabilization of renal function after renal denervation in patients with CKD stage 3 in parallel to a significant decrease in BP [29 ].”
Self-citationHypertension-Induced Renal Injury: From Pathophysiology to Therapeutic Perspectives
Zhou, N., Zhong, S.-Y., Gao, P., He, F.-F., & Zhang, C. (2026) · Biomedicines · doi:10.3390/biomedicines14030595 · Cited by 9
Possible organ-protective effects of renal denervation: insights from basic studies
Akumwami, S., Morishita, A., Iradukunda, A., Kobara, H., & Nishiyama, A. (2023) · Hypertension Research · doi:10.1038/s41440-023-01393-w · Cited by 9
“Furthermore, RDN normalizes blood pressure and improves renal function in patients and animals with hypertensive chronic kidney disease (CKD) [16 – 19].”
BackgroundZhang, J., Belford, P. M., & Stouffer, G. A. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14103554 · Cited by 6
“With ongoing research and emerging clinical data, it is reasonable to project that the indications for RDN may eventually expand to include patients with advanced CKD, pending further evidence on safety, efficacy, and long-term clinical outcomes [34].”
Kario, K., Kandzari, D. E., Mahfoud, F., Weber, M. A., Schmieder, R. E., Tsioufis, K. P., Liu, M., Böhm, M., & Townsend, R. R. (2025) · Hypertension Research · doi:10.1038/s41440-025-02186-z · Cited by 5
“High sympathetic activity is also commonly associated with CKD suggesting that RDN may be especially bene fi cial in this population [31].”
Self-citationMulti-Organ Denervation: The Past, Present and Future
Haider, S. A., Sharif, R., & Sharif, F. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14082746 · Cited by 5
“Hypertension [26] Arrhythmia [27] Dysglycaemia [28] Obstructive sleep apnoea [29] Chronic kidney disease [30] Heart failure [31] Common hepatic artery Dysglycaemia [32] Dyslipidaemia/insulin resistance [33] Hypertension [34] Liver cirrhosis [35] Splenic artery Hypertension [36] Hypertrophic…”
Bharadwaj, H. R., Tan, J. K., Ali, S. H., Aderinto, N., Shah, M. H., Marsool, M. D. M., Jain, J., & Dalal, P. (2023) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2023.102357 · Cited by 3
Doul, J., Gawryś, O., Škaroupková, P., Vaňourková, Z., Bačová, B. S., Sýkora, M., Maxová, H., Hošková, L., Šnorek, M., Sadowski, J., et al. (2024) · Physiological Research · doi:10.33549/physiolres.935469 · Cited by 3
Renal denervation increases capillary density in hypertensive patients
Bosch, A., Harazny, J. M., Schmid, A., Kannenkeril, D., Karg, M. V., Bytyqi, V., Roth, H., Schiffer, M., Uder, M., & Schmieder, R. E. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf387 · Cited by 3
Self-citationManukyan, M., Mordovin, V. F., Pekarskiy, S. E., Zyubanova, I. V., Lichikaki, V. A., Solonskaya, E., Хунхинова, С. А., Gusakova, A., & Falkovskaya, А. Y. (2026) · Medicina · doi:10.3390/medicina62020274 · Cited by 2
“Moreover, patients with CKD may derive even greater benefit compared to those without renal impairment [23].”
Renal Denervation: A New Era in the Management of Resistant Hypertension
Abid, S., Mehta, S., Munazzah, F., Yager, N., Baloch, S., & Hongalgi, K. D. (2025) · Kidney360 · doi:10.34067/kid.0000000961 · Cited by 2
“3,22 Table 2 further enlists patient eligibility criteria for RDN based on guidance from 2024 Scienti fi c Statement from AHA.”
Pleiotropic effects of renal denervation beyond blood pressure reduction
Vakka, A., Kyriakoulis, K. G., Tatakis, F., Iliakis, P., Kalliakouda, E., Papadomarkaki, K., Damianaki, A., Dimitriadis, K. P., Konstantinidis, D., & Tsioufis, K. P. (2026) · Hypertension Research · doi:10.1038/s41440-026-02699-1 · Cited by 1
“According to data from observational studies, RDN may also lead to a slowdown in further deterioration of renal function, even independent of its effects on BP reduction, indicating the potential nephroprotective effect of RDN [37, 38].”
Lee, M.-S., Oh, S., Jung, W.-N., Noh, J.-W., Ahn, Y., Ahn, S.-Y., & Lee, B.-C. (2022) · The Journal of Internal Korean Medicine · doi:10.22246/jikm.2022.43.5.1037 · Cited by 1
Selecting patients for interventional procedures to treat hypertension
Lobo, M. D., Rull, G., Saxena, M., & Kapil, V. (2023) · Blood Pressure · doi:10.1080/08037051.2023.2248276 · Cited by 3
“In contrast, presence of chronic kidney disease is not a contraindication to RDN or other interventional approaches until the patient reaches end-stage kidney disease and trials are ongoing to ascertain whether even in this group there is benefit from RDN for BP control) [63].”
BackgroundLarina, V. N., Алексеевна, В. Е., Fedorova, E. V., Mikhaylusova, M. P., Saino, O. V., & Mironova, T. N. (2023) · Cardiosomatics · doi:10.17816/cs567844 · Cited by 2
A Promising Approach in the Treatment of Resistant Hypertension: Renal Denervation
(2023) · Advancements in Journal of Urology and Nephrology · doi:10.33140/ajun.05.02.03
Hypertension in Patients on Hemodialysis: Looking Beyond Stable Sessions
Jamboti, J. S., & Anupama, Y. J. (2024) · Indian Journal of Kidney Diseases · doi:10.4103/ijkd.ijkd_10_24
Renal Artery Denervation for the Management of Hypertension: Current Trends and Future Direction
Naqvi, S. Y., Shah, M. U., Renner, M., Kouloumpinis, A., Qamar, M. J. U., Ali, A., Goldberg, S., & Thackray, S. D. R. (2024) · The American Journal of Medicine · doi:10.1016/j.amjmed.2024.06.029 · Cited by 2
Renal denervation benefits in chronic kidney disease: An updated review
Habas, E. M., Alarbi, K. M. S., Habas, A. M., Baghi, M. A. M., Habas, E., Rayani, A., Said, A., Farfar, K., Errayes, A., Alfitori, G. B., et al. (2024) · Yemen Journal of Medicine · doi:10.18231/j.yjom.2024.004
Vasoactive Substances as Mediators of Renal Injury
Caceres, P. S., & Rossi, N. F. (2025) · Elsevier eBooks · doi:10.1016/b978-0-323-95488-4.00105-4
Treatment of Hypertension in Chronic Kidney Disease
Redón, J. (2025) · Updates in hypertension and cardiovascular protection · doi:10.1007/978-3-031-81292-7_15
The Use of Renal Artery Denervation in Atrial Fibrillation Patients: A Review of Literature
Shudayfat, Q., Shitawi, J., Al-Jafari, M., Quran, S., Owaidat, J. F., Nofal, M. A., Abu‐Jeyyab, M., Daseh, A. I., & Zuaiter, S. (2025) · High Yield Medical Reviews · doi:10.59707/hymreiws7701
“RDN might not be renal protective in some situations including bile duct ligation-induced renal failure and ischemia/reperfusion-induced acute kidney injury [27].”
Waqas, M., Ullah, Z., & Mohammad, N. (2025) · Journal of Pak International Medical College · doi:10.64911/2ah9dp16
Lynch, H., & Lynch, H. (2023) · UA Campus Repository (The University of Arizona)
Zero-Contrast Percutaneous Renal Denervation Guided by Multimodal Image Fusion
Ma, R., Dong, X., Zhang, L., Yang, K., Zhang, J., Qin, L., Li, C., Chen, F. F., Liao, W., & Wang, S. (2026) · JACC Case Reports · doi:10.1016/j.jaccas.2026.107051
Jonas, M., Ayyad, O., Alnees, M., Kirzhner, A., Schiller, T., Spaulding, C. M., Darwish, A., Mahamid, A., Tuvali, O., Hassan, A., et al. (2026) · Kidney & Blood Pressure Research · doi:10.1159/000551407
Renal Denervation for Uncontrolled Hypertension: A Measurement-First, Program-Based Approach
Szarpak, Ł., Katipoğlu, B., Jaguszewski, M. J., Baier, A., Kubica, J., Maslyk, M. M., Pruc, M., Momot, K., Cander, B., & Lin, Q. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15072648
Renal Denervation in Cardiovascular Diseases: Mechanisms, Evidence, and Expanding Applications
Awashra, A., Neiroukh, H., Alnatour, L., Jibril, N. S., AbuBaha, M., Emara, A., Shehadeh, W., Zahran, A., Elgendy, M. S., Shubietah, A. R. M., et al. (2026) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.70656 · Cited by 1
Khanna, S., & Kaur, D. R. (2026) · KIDNEYS · doi:10.65327/kidneys.v15i1.597
Scalise, F., Toscano, E., Sorropago, A., Amman, C., & Grassi, G. M. (2026) · Updates in hypertension and cardiovascular protection · doi:10.1007/978-3-032-29564-4_4
Mohammed, M., Ekperikpe, U. S., Nair, S. S., Lazartigues, E. D., Tewari, A. K., & Padanilam, B. J. (2026) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000001196
Shimokawa, T., IWAMOTO, A., & Tamura, Y. (2026) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2026.179370
Ostadebrahimi, H., Tashakori-Miyanroudi, M., Khodadadizadeh, A., & Souresrafil, A. (2026) · Journal of preventive medicine and hygiene
Schmieder, R. E., Kannenkeril, D., Böhm, M., Mahfoud, F., Rump, L. C., Stegbauer, J., van der Giet, M., Meyer, M. R., Schiffer, M., Veelken, R. A., et al. (2026) · Journal of Hypertension · doi:10.1097/hjh.0000000000004482
Self-citation
Metadata
- Authors
- Schmieder, R. E.
- Affiliations
- Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
- Corresponding author
- Schmieder, Roland E
- ORCID
- Schmieder, Roland E
- Venue
- Nephrology Dialysis Transplantation
- Publisher
- Oxford University Press (OUP)
- Published
- 2022-05-25
- Volume
- 38
- Issue
- 5
- Pages
- 1089-1096
- ISSN
- 0931-0509 (ISSN-L)
- 1460-2385
- PMC
- PMC10157753
- OpenAlex
- W4281568867
- Cited by
- 39
- References
- 65
- Citations by year
- 2026: 9 · 2025: 13 · 2024: 6 · 2023: 10 · 2022: 1
- FWCI
- 1.53
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Nephrology Dialysis Transplantation (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- Medtronic
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Nephrology › Renal and Vascular Pathologies
- Keywords
- renal denervation, chronic kidney disease, hypertension, catheter ablation, sympathetic hyperactivity, renal protection, adjunctive therapy, antihypertensive therapy
- MeSH terms
- Antihypertensive Agents, Blood Pressure, Denervation, Humans, Hypertension, Kidney, Sympathectomy, Treatment Outcome, Renal Insufficiency, Chronic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.